Labcorp (NYSE:LH) Releases FY 2026 Earnings Guidance

Labcorp (NYSE:LH) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 18.100-18.550 for the period, compared to the consensus earnings per share estimate of 18.340. The company issued revenue guidance of $14.7 billion-$14.8 billion, compared to the consensus revenue estimate of $14.7 billion.

Labcorp Stock Down 0.5%

Labcorp stock opened at $323.04 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80. The stock has a market cap of $26.20 billion, a PE ratio of 26.72, a price-to-earnings-growth ratio of 1.84 and a beta of 0.88. Labcorp has a fifty-two week low of $244.52 and a fifty-two week high of $341.80. The firm’s 50-day simple moving average is $313.65 and its 200 day simple moving average is $282.90.

Labcorp (NYSE:LH) last issued its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, topping analysts’ consensus estimates of $4.78 by $0.21. The business had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.71 billion. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.Labcorp’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the company posted $4.35 earnings per share. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Research analysts predict that Labcorp will post 18.32 EPS for the current fiscal year.

Labcorp Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 28th were given a dividend of $0.72 per share. The ex-dividend date was Friday, August 28th. This represents a $2.88 annualized dividend and a yield of 0.9%. Labcorp’s dividend payout ratio is presently 23.82%.

Analysts Set New Price Targets

LH has been the topic of several research reports. Piper Sandler lifted their price objective on shares of Labcorp from $300.00 to $309.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Truist Financial raised their price target on shares of Labcorp from $320.00 to $350.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Weiss Ratings upgraded Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, July 24th. Robert W. Baird set a $352.00 price objective on Labcorp in a report on Friday, July 31st. Finally, Bank of America upped their price objective on shares of Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a report on Monday, July 13th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $336.36.

Insider Transactions at Labcorp

In related news, Director Kerrii B. Anderson sold 3,000 shares of Labcorp stock in a transaction on Monday, August 17th. The stock was sold at an average price of $318.02, for a total transaction of $954,060.00. Following the completion of the sale, the director owned 6,563 shares of the company’s stock, valued at approximately $2,087,165.26. This trade represents a 31.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Amy B. Summy sold 924 shares of the business’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $306.74, for a total value of $283,427.76. Following the transaction, the executive vice president directly owned 6,956 shares of the company’s stock, valued at $2,133,683.44. The trade was a 11.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 8,919 shares of company stock worth $2,826,593. 0.84% of the stock is owned by corporate insiders.

About Labcorp

Labcorp (NYSE: LH), formerly Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing and related services to physicians, hospitals, health systems, employers, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including molecular, genetic, oncology, women’s health, infectious disease and pathology services.